Key Points
- CEO Zhenya Lindgardt sold shares: Lindgardt sold 4,155 shares on Dec. 10 at an average $3.31 (≈$13,753) and 28,215 shares on Dec. 9 at $3.04 (≈$85,774), leaving her with 763,926 shares — a 0.54% reduction in her position.
- Stock and fundamentals: Sera shares rose 7.5% to $3.66 on light volume, with a market cap of $141.1M and a 52-week range of $1.37–$9.13; the company reported a beat on EPS (-$0.16 vs. -$0.19) but weak revenue and remains viewed negatively by analysts with an average "Sell" rating.
Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CEO Zhenya Lindgardt sold 4,155 shares of Sera Prognostics stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $3.31, for a total transaction of $13,753.05. Following the transaction, the chief executive officer owned 763,926 shares of the company's stock, valued at approximately $2,528,595.06. The trade was a 0.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Zhenya Lindgardt also recently made the following trade(s):
- On Tuesday, December 9th, Zhenya Lindgardt sold 28,215 shares of Sera Prognostics stock. The shares were sold at an average price of $3.04, for a total transaction of $85,773.60.
Sera Prognostics Stock Up 7.5%
Shares of Sera Prognostics stock traded up $0.26 during trading on Friday, hitting $3.66. 4,581 shares of the company were exchanged, compared to its average volume of 168,315. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13. The stock has a market capitalization of $141.08 million, a price-to-earnings ratio of -4.75 and a beta of 0.97. The firm has a 50 day moving average price of $3.18 and a 200 day moving average price of $2.79.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.10 million. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%. Analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.
Hedge Funds Weigh In On Sera Prognostics
Institutional investors have recently added to or reduced their stakes in the business. Abel Hall LLC acquired a new stake in Sera Prognostics in the 2nd quarter worth about $31,000. Wagner Wealth Management LLC acquired a new position in shares of Sera Prognostics during the 2nd quarter valued at about $34,000. Riverview Capital Advisers LLC purchased a new position in shares of Sera Prognostics during the 2nd quarter worth about $35,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Sera Prognostics during the 3rd quarter worth about $38,000. Finally, XTX Topco Ltd acquired a new stake in shares of Sera Prognostics in the first quarter worth approximately $39,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research firms recently commented on SERA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Sera Prognostics in a research report on Monday. Wall Street Zen raised shares of Sera Prognostics from a "sell" rating to a "hold" rating in a research note on Saturday, October 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sera Prognostics currently has an average rating of "Sell".
View Our Latest Research Report on SERA
About Sera Prognostics
(
Get Free Report)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
